{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:49:01Z","timestamp":1793922541233,"version":"4.8.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-08836-4","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T10:46:31Z","timestamp":1744886791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Adjunctive ketamine vs. buprenorphine in co-occurring major depressive disorder and opioid use disorder: a randomized, double-blind clinical trial assessing anxiety symptom severity and craving intensity"],"prefix":"10.1186","volume":"26","author":[{"given":"Arash","family":"Mansoori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Bazrafshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshid","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Hamdollah","family":"Mosavat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"8836_CR1","doi-asserted-by":"crossref","unstructured":"Adzic M, Lukic I, Mitic M, Glavonic E, Dragicevic N, Ivkovic S. Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine. Life Sci. 2023;326:121803.","DOI":"10.1016\/j.lfs.2023.121803"},{"key":"8836_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-018-3055-z","volume":"19","author":"J Ahmadi","year":"2018","unstructured":"Ahmadi J, Jahromi MS, Ghahremani D, London ED. Single high-dose buprenorphine for opioid craving during withdrawal. Trials. 2018;19:1\u20137.","journal-title":"Trials"},{"key":"8836_CR3","doi-asserted-by":"crossref","unstructured":"Ahmadi J, Mansoori A, Mosavat SH, Bazrafshan A. Comparison of ketamine with buprenorphine as adjunctive therapy in the treatment of comorbid major depressive disorder and opium use disorders: a randomized controlled trial. Int J Psychiatry Med. 2023:00912174231225087.","DOI":"10.1177\/00912174231225087"},{"key":"8836_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13063-017-2007-3","volume":"18","author":"J Ahmadi","year":"2017","unstructured":"Ahmadi J, Razeghian Jahromi L. Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial. Trials. 2017;18:259.","journal-title":"Trials"},{"key":"8836_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-019-3554-6","volume":"20","author":"J Ahmadi","year":"2019","unstructured":"Ahmadi J, Sahraian A, Biuseh M. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving. Trials. 2019;20:1\u20137.","journal-title":"Trials"},{"key":"8836_CR6","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s13063-019-3554-6","volume":"20","author":"J Ahmadi","year":"2019","unstructured":"Ahmadi J, Sahraian A, Biuseh M. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving. Trials. 2019;20:468.","journal-title":"Trials"},{"key":"8836_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4103\/tcmj.tcmj_220_18","volume":"32","author":"J Ahmadi","year":"2020","unstructured":"Ahmadi J, Sarani EM, Jahromi MS. Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: a randomized, double blind, placebo-controlled study. Tzu Chi Med J. 2020;32:58\u201364.","journal-title":"Tzu Chi Med J"},{"key":"8836_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4103\/tcmj.tcmj_220_18","volume":"32","author":"J Ahmadi","year":"2020","unstructured":"Ahmadi J, Sarani EM, Jahromi MS. Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: a randomized, double blind, placebo-controlled study. Tzu-Chi Med J. 2020;32:58.","journal-title":"Tzu-Chi Med J"},{"key":"8836_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1503\/jpn.160175","volume":"42","author":"LR Aleksandrova","year":"2017","unstructured":"Aleksandrova LR, Phillips AG, Wang YT. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry Neurosci. 2017;42:222\u20139.","journal-title":"J Psychiatry Neurosci"},{"key":"8836_CR10","doi-asserted-by":"publisher","first-page":"10009","DOI":"10.3389\/adar.2021.10009","volume":"1","author":"CM Cameron","year":"2021","unstructured":"Cameron CM, Nieto S, Bosler L, Wong M, Bishop I, Mooney L, Cahill CM. Mechanisms underlying the anti-suicidal treatment potential of buprenorphine. Adv Drug Alcohol Res. 2021;1:10009.","journal-title":"Adv Drug Alcohol Res."},{"key":"8836_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1124\/jpet.105.092304","volume":"316","author":"WA Carlezon","year":"2006","unstructured":"Carlezon WA, Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY-W, Cohen BM. Depressive-like effects of the \u03ba-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther. 2006;316:440\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"8836_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s40265-020-01373-1","volume":"80","author":"RM Chalhoub","year":"2020","unstructured":"Chalhoub RM, Kalivas PW. Non-opioid treatments for opioid use disorder: rationales and data to date. Drugs. 2020;80:1509\u201324.","journal-title":"Drugs"},{"key":"8836_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3390\/ijerph18010341","volume":"18","author":"R Damiescu","year":"2021","unstructured":"Damiescu R, Banerjee M, Lee DY, Paul NW, Efferth T. Health (care) in the crisis: reflections in science and society on opioid addiction. Int J Environ Res Public Health. 2021;18:341.","journal-title":"Int J Environ Res Public Health"},{"key":"8836_CR14","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1080\/14656566.2017.1409722","volume":"18","author":"M Dematteis","year":"2017","unstructured":"Dematteis M, Auriacombe M, D\u2019Agnone O, Somaini L, Szerman N, Littlewood R, Alam F, Alho H, Benyamina A, Bobes J. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother. 2017;18:1987\u201399.","journal-title":"Expert Opin Pharmacother"},{"key":"8836_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/nyas.12646","volume":"1345","author":"KE DeWilde","year":"2015","unstructured":"DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015;1345:47\u201358.","journal-title":"Ann N Y Acad Sci"},{"key":"8836_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jad.2020.03.089","volume":"271","author":"A Dinoff","year":"2020","unstructured":"Dinoff A, Lynch ST, Sekhri N, Klepacz L. A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression. J Affect Disord. 2020;271:91\u20139.","journal-title":"J Affect Disord"},{"key":"8836_CR17","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/0269881115573809","volume":"29","author":"KS El Iskandrani","year":"2015","unstructured":"El Iskandrani KS, Oosterhof CA, El Mansari M, Blier P. Impact of subanesthetic doses of ketamine on AMPA-mediated responses in rats: an in vivo electrophysiological study on monoaminergic and glutamatergic neurons. J Psychopharmacol. 2015;29:792\u2013801.","journal-title":"J Psychopharmacol"},{"key":"8836_CR18","doi-asserted-by":"publisher","first-page":"15726","DOI":"10.1523\/JNEUROSCI.1856-10.2010","volume":"30","author":"S Erk","year":"2010","unstructured":"Erk S, Mikschl A, Stier S, Ciaramidaro A, Gapp V, Weber B, Walter H. Acute and sustained effects of cognitive emotion regulation in major depression. J Neurosci. 2010;30:15726\u201334.","journal-title":"J Neurosci"},{"key":"8836_CR19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00228-022-03303-4","volume":"78","author":"D Fluyau","year":"2022","unstructured":"Fluyau D, Mitra P, Jain A, Kailasam VK, Pierre CG. Selective serotonin reuptake inhibitors in the treatment of depression, anxiety, and post-traumatic stress disorder in substance use disorders: a Bayesian meta-analysis. Eur J Clin Pharmacol. 2022;78:931\u201342.","journal-title":"Eur J Clin Pharmacol"},{"key":"8836_CR20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41398-019-0506-6","volume":"9","author":"N Gass","year":"2019","unstructured":"Gass N, Becker R, Reinwald J, Cosa-Linan A, Sack M, Weber-Fahr W, Vollmayr B, Sartorius A. Differences between ketamine\u2019s short-term and long-term effects on brain circuitry in depression. Transl Psychiatry. 2019;9:172.","journal-title":"Transl Psychiatry"},{"key":"8836_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s40473-018-0139-8","volume":"5","author":"DM Gerhard","year":"2018","unstructured":"Gerhard DM, Duman RS. Rapid-acting antidepressants: mechanistic insights and future directions. Curr Behav Neurosci Rep. 2018;5:36\u201347.","journal-title":"Curr Behav Neurosci Rep"},{"key":"8836_CR22","unstructured":"Giron SE, Lai G, Griffis CA, Zhang SJ. Demystifying Buprenorphine with Current Evidence-Based Practice in Acute and Chronic Pain Management. AANA J. 2022;90(3):225\u201333."},{"key":"8836_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12325-021-01861-0","volume":"38","author":"GM Goodwin","year":"2021","unstructured":"Goodwin GM. Revisiting Treatment Options for Depressed Patients with Generalised Anxiety Disorder. Adv Ther. 2021;38:61\u20138.","journal-title":"Adv Ther"},{"key":"8836_CR24","unstructured":"Grinspoon P. Ketamine for treatment-resistant depression: when and where is it safe. Harvard Health. 2022."},{"key":"8836_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/pcn.12902","volume":"73","author":"K Hashimoto","year":"2019","unstructured":"Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci. 2019;73:613\u201327.","journal-title":"Psychiatry Clin Neurosci"},{"key":"8836_CR26","doi-asserted-by":"publisher","first-page":"e13282","DOI":"10.1111\/adb.13282","volume":"28","author":"B Holen","year":"2023","unstructured":"Holen B, Shadrin AA, Icick R, Filiz TT, Hindley G, R\u00f8devand L, O\u2019Connell KS, Hagen E, Frei O, Bahrami S, Cheng W, Parker N, Tesfaye M, Jaho\u0142kowski P, Karadag N, Dale AM, Djurovic S, Smeland OB, Andreassen OA. Genome-wide analyses reveal novel opioid use disorder loci and genetic overlap with schizophrenia, bipolar disorder, and major depression. Addict Biol. 2023;28:e13282.","journal-title":"Addict Biol"},{"key":"8836_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/14656566.2020.1732349","volume":"21","author":"LE Hood","year":"2020","unstructured":"Hood LE, Leyrer-Jackson JM, Olive MF. Pharmacotherapeutic management of co-morbid alcohol and opioid use. Expert Opin Pharmacother. 2020;21:823\u201339.","journal-title":"Expert Opin Pharmacother"},{"key":"8836_CR28","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","volume":"176","author":"YL Hurd","year":"2019","unstructured":"Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, Oprescu AM, Salsitz E. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019;176:911\u201322.","journal-title":"Am J Psychiatry"},{"key":"8836_CR29","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.2147\/NDT.S246294","volume":"16","author":"T Inoue","year":"2020","unstructured":"Inoue T, Kimura T, Inagaki Y, Shirakawa O. Prevalence of comorbid anxiety disorders and their associated factors in patients with bipolar disorder or major depressive disorder. Neuropsychiatr Dis Treat. 2020;16:1695\u2013704.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"8836_CR30","doi-asserted-by":"publisher","unstructured":"Ionescu DF, Niciu MJ, Richards EM, Zarate CA Jr. Pharmacologic treatment of dimensional anxious depression: a review. Prim Care Companion CNS Disord. 2014;16(3):PCC.13r01621. https:\/\/doi.org\/10.4088\/PCC.13r01621.","DOI":"10.4088\/PCC.13r01621"},{"key":"8836_CR31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fpsyt.2018.00277","volume":"9","author":"JL Jones","year":"2018","unstructured":"Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE. Efficacy of ketamine in the treatment of substance use disorders: a systematic review. Front Psych. 2018;9:277.","journal-title":"Front Psych"},{"key":"8836_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/ijnp\/pyy094","volume":"22","author":"B Kadriu","year":"2019","unstructured":"Kadriu B, Musazzi L, Henter ID, Graves M, Popoli M, Zarate CA Jr. Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments. Int J Neuropsychopharmacol. 2019;22:119\u201335.","journal-title":"Int J Neuropsychopharmacol"},{"key":"8836_CR33","first-page":"170","volume":"5","author":"L Lalanne","year":"2014","unstructured":"Lalanne L, Ayranci G, Kieffer BL, Lutz P-E. The kappa opioid receptor: from addiction to depression, and back. Front Psych. 2014;5:170.","journal-title":"Front Psych"},{"key":"8836_CR34","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1523\/JNEUROSCI.4458-07.2008","volume":"28","author":"BB Land","year":"2008","unstructured":"Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin \u03ba-opioid system. J Neurosci. 2008;28:407\u201314.","journal-title":"J Neurosci"},{"key":"8836_CR35","doi-asserted-by":"publisher","first-page":"1274719","DOI":"10.3389\/fpubh.2023.1274719","volume":"11","author":"YK Lee","year":"2024","unstructured":"Lee YK, Gold MS, Blum K, Thanos PK, Hanna C, Fuehrlein BS. Opioid use disorder: current trends and potential treatments. Front Public Health. 2024;11:1274719.","journal-title":"Front Public Health"},{"key":"8836_CR36","doi-asserted-by":"publisher","first-page":"204512532091665","DOI":"10.1177\/2045125320916657","volume":"10","author":"D Matveychuk","year":"2020","unstructured":"Matveychuk D, Thomas RK, Swainson J, Khullar A, MacKay M-A, Baker GB, Dursun SM. Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Ther Adv Psychopharmacol. 2020;10:2045125320916657.","journal-title":"Ther Adv Psychopharmacol."},{"key":"8836_CR37","doi-asserted-by":"publisher","first-page":"e1003901","DOI":"10.1371\/journal.pmed.1003901","volume":"19","author":"M Moitra","year":"2022","unstructured":"Moitra M, Santomauro D, Collins PY, Vos T, Whiteford H, Saxena S, Ferrari AJ. The global gap in treatment coverage for major depressive disorder in 84 countries from 2000\u20132019: a systematic review and Bayesian meta-regression analysis. PLoS Med. 2022;19:e1003901.","journal-title":"PLoS Med"},{"key":"8836_CR38","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1017\/S0033291715001506","volume":"45","author":"JW Murrough","year":"2015","unstructured":"Murrough JW, Soleimani L, DeWilde K, Collins K, Lapidus K, Iacoviello B, Lener M, Kautz M, Kim J, Stern J. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;45:3571\u201380.","journal-title":"Psychol Med"},{"key":"8836_CR39","doi-asserted-by":"crossref","unstructured":"Nikolin S, Rodgers A, Schwaab A, Bahji A, Zarate C, Jr, Vazquez G, Loo C. Ketamine for the treatment of major depression: a systematic review and meta-analysis. eClin Med. 2023:62.","DOI":"10.1016\/j.eclinm.2023.102127"},{"key":"8836_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/09540261.2023.2229430","volume":"35","author":"D Oliveira","year":"2023","unstructured":"Oliveira D, Fontenele R, Weleff J, Sofuoglu M, De Aquino JP. Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence. Int Rev Psychiatry. 2023;35:377\u201396.","journal-title":"Int Rev Psychiatry"},{"key":"8836_CR41","first-page":"735","volume":"22","author":"S Page","year":"2019","unstructured":"Page S, Mavrikaki MM, Lintz T, Puttick D, Roberts E, Rosen H, Carroll FI, Carlezon WA, Chartoff EH. Behavioral pharmacology of novel kappa opioid receptor antagonists in rats. Int J Neuropsychopharmacol. 2019;22:735\u201345.","journal-title":"Int J Neuropsychopharmacol"},{"key":"8836_CR42","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1016\/j.neuron.2021.09.011","volume":"109","author":"AF Pardi\u00f1as","year":"2021","unstructured":"Pardi\u00f1as AF, Owen MJ, Walters JT. Pharmacogenomics: A road ahead for precision medicine in psychiatry. Neuron. 2021;109:3914\u201329.","journal-title":"Neuron"},{"key":"8836_CR43","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/17512433.2019.1635454","volume":"12","author":"S Parida","year":"2019","unstructured":"Parida S, Carroll KM, Petrakis IL, Sofuoglu M. Buprenorphine treatment for opioid use disorder: recent progress. Expert Rev Clin Pharmacol. 2019;12:791\u2013803.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"8836_CR44","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41380-018-0329-5","volume":"24","author":"SA Pendergrass","year":"2019","unstructured":"Pendergrass SA, Crist RC, Jones LK, Hoch JR, Berrettini WH. The importance of buprenorphine research in the opioid crisis. Mol Psychiatry. 2019;24:626\u201332.","journal-title":"Mol Psychiatry"},{"key":"8836_CR45","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/jcpt.13114","volume":"45","author":"JV Pergolizzi Jr","year":"2020","unstructured":"Pergolizzi JV Jr, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management. J Clin Pharm Ther. 2020;45:892\u2013903.","journal-title":"J Clin Pharm Ther"},{"key":"8836_CR46","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41386-019-0570-x","volume":"45","author":"JL Phillips","year":"2020","unstructured":"Phillips JL, Norris S, Talbot J, Hatchard T, Ortiz A, Birmingham M, Owoeye O, Batten LA, Blier P. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology. 2020;45:606\u201312.","journal-title":"Neuropsychopharmacology"},{"key":"8836_CR47","doi-asserted-by":"publisher","first-page":"101978","DOI":"10.1016\/j.cpr.2021.101978","volume":"84","author":"AH Rogers","year":"2021","unstructured":"Rogers AH, Zvolensky MJ, Ditre JW, Buckner JD, Asmundson GJG. Association of opioid misuse with anxiety and depression: a systematic review of the literature. Clin Psychol Rev. 2021;84:101978.","journal-title":"Clin Psychol Rev"},{"key":"8836_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/1570159X14666160309114549","volume":"15","author":"S Wohleb","year":"2017","unstructured":"Wohleb S, E., Gerhard, D., Thomas, A., S Duman, R.,. Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine. Curr Neuropharmacol. 2017;15:11\u201320.","journal-title":"Curr Neuropharmacol"},{"key":"8836_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/YCO.0000000000000903","volume":"37","author":"G Sampogna","year":"2024","unstructured":"Sampogna G, Toni C, Catapano P, Della Rocca B, Di Vincenzo M, Luciano M, Fiorillo A. New trends in personalized treatment of depression. Curr Opin Psychiatry. 2024;37:3\u20138.","journal-title":"Curr Opin Psychiatry"},{"key":"8836_CR50","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/da.22536","volume":"33","author":"S Sassano-Higgins","year":"2016","unstructured":"Sassano-Higgins S, Baron D, Juarez G, Esmaili N, Gold M. A review of ketamine abuse and diversion. Depress Anxiety. 2016;33:718\u201327.","journal-title":"Depress Anxiety"},{"key":"8836_CR51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1146\/annurev-clinpsy-021815-093351","volume":"12","author":"MA Sayette","year":"2016","unstructured":"Sayette MA. The role of craving in substance use disorders: theoretical and methodological issues. Annu Rev Clin Psychol. 2016;12:407\u201333.","journal-title":"Annu Rev Clin Psychol"},{"key":"8836_CR52","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.3390\/ijms19082410","volume":"19","author":"G Serafini","year":"2018","unstructured":"Serafini G, Adavastro G, Canepa G, De Berardis D, Valchera A, Pompili M, Nasrallah H, Amore M. The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review. Int J Mol Sci. 2018;19:2410.","journal-title":"Int J Mol Sci"},{"key":"8836_CR53","doi-asserted-by":"publisher","unstructured":"Shalimova A, Babasieva V, Chubarev VN, Tarasov VV, Schi\u00f6th HB, Mwinyi J. Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics. 2021;22(8):485-503. https:\/\/doi.org\/10.2217\/pgs-2020-0157.","DOI":"10.2217\/pgs-2020-0157"},{"key":"8836_CR54","doi-asserted-by":"crossref","unstructured":"Shenoi NC, Yurewicz M. Co-occurring psychiatric and substance use disorders. pharmacotherapy for complex substance use disorders: a practical guide. 2023:199.","DOI":"10.1176\/appi.books.9781615379989.lg10"},{"key":"8836_CR55","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.addbeh.2018.03.020","volume":"84","author":"G Stathopoulou","year":"2018","unstructured":"Stathopoulou G, Pollack MH, Otto MW. Anxiety sensitivity moderates drug cravings in response to induced negative affect in opioid dependent outpatients. Addict Behav. 2018;84:75\u20138.","journal-title":"Addict Behav"},{"key":"8836_CR56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","volume":"6","author":"J Strang","year":"2020","unstructured":"Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, Marshall BD, Tyndall M, Walsh SL. Opioid use disorder. Nat Rev Dis Primers. 2020;6:3.","journal-title":"Nat Rev Dis Primers"},{"key":"8836_CR57","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/npp.2017.94","volume":"42","author":"TP Su","year":"2017","unstructured":"Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, Tu PC, Bai YM, Cheng CM, Krystal JH. Dose-Related effects of adjunctive ketamine in taiwanese patients with treatment-resistant depression. Neuropsychopharmacol. 2017;42:2482\u201392.","journal-title":"Neuropsychopharmacol"},{"key":"8836_CR58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2174\/1570159X13666150727220944","volume":"14","author":"T Taylor","year":"2016","unstructured":"Taylor T, G., Manzella, F.,. Kappa opioids, salvinorin A and major depressive disorder. Curr Neuropharmacol. 2016;14:165\u201376.","journal-title":"Curr Neuropharmacol"},{"key":"8836_CR59","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1503\/jpn.190073","volume":"44","author":"J Talbot","year":"2019","unstructured":"Talbot J, Phillips JL, Blier P. Ketamine for chronic depression: two cautionary tales. J Psychiatry Neurosci. 2019;44:384\u20135.","journal-title":"J Psychiatry Neurosci"},{"key":"8836_CR60","first-page":"2097","volume":"10","author":"P Thaipisuttikul","year":"2014","unstructured":"Thaipisuttikul P, Ittasakul P, Waleeprakhon P, Wisajun P, Jullagate S. Psychiatric comorbidities in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:2097\u2013103.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"8836_CR61","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","volume":"99","author":"ND Volkow","year":"2019","unstructured":"Volkow ND, Michaelides M, Baler R. The neuroscience of drug reward and addiction. Physiol Rev. 2019;99:2115\u201340.","journal-title":"Physiol Rev"},{"key":"8836_CR62","doi-asserted-by":"crossref","unstructured":"Walsh SL, Middleton LS. Buprenorphine pharmacodynamics and pharmacokinetics, Handbook of methadone prescribing and buprenorphine therapy. Springer. 2013:163\u2013181.","DOI":"10.1007\/978-1-4614-6974-2_12"},{"key":"8836_CR63","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.chest.2020.03.010","volume":"158","author":"X Wang","year":"2020","unstructured":"Wang X, Ji X. Sample size estimation in clinical research: from randomized controlled trials to observational studies. Chest. 2020;158:S12\u201320.","journal-title":"Chest"},{"key":"8836_CR64","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bbrc.2022.01.024","volume":"594","author":"Y-T Wang","year":"2022","unstructured":"Wang Y-T, Zhang N-N, Liu L-J, Jiang H, Hu D, Wang Z-Z, Chen N-H, Zhang Y. Glutamatergic receptor and neuroplasticity in depression: implications for ketamine and rapastinel as the rapid-acting antidepressants. Biochem Biophys Res Commun. 2022;594:46\u201356.","journal-title":"Biochem Biophys Res Commun"},{"key":"8836_CR65","volume-title":"Mu opioid receptor-positive neurons in the dorsal raphe nucleus: role in reward","author":"L Welsch","year":"2022","unstructured":"Welsch L. Mu opioid receptor-positive neurons in the dorsal raphe nucleus: role in reward. Emotional Responses and Morphine Abstinence: McGill University (Canada); 2022."},{"key":"8836_CR66","doi-asserted-by":"publisher","first-page":"e220194","DOI":"10.1001\/jamanetworkopen.2022.0194","volume":"5","author":"I Yunusa","year":"2022","unstructured":"Yunusa I, Gagne JJ, Yoshida K, Bykov K. Risk of opioid overdose associated with concomitant use of oxycodone and selective serotonin reuptake inhibitors. JAMA Netw Open. 2022;5:e220194\u2013e220194.","journal-title":"JAMA Netw Open"},{"key":"8836_CR67","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","volume":"71","author":"CA Zarate Jr","year":"2012","unstructured":"Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA. Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiat. 2012;71:939\u201346.","journal-title":"Biol Psychiat"},{"key":"8836_CR68","doi-asserted-by":"publisher","first-page":"e86022","DOI":"10.7554\/eLife.86022","volume":"12","author":"A Zaytseva","year":"2023","unstructured":"Zaytseva A, Bouckova E, Wiles MJ, Wustrau MH, Schmidt IG, Mendez-Vazquez H, Khatri L, Kim S. Ketamine\u2019s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors. Elife. 2023;12:e86022.","journal-title":"Elife"},{"key":"8836_CR69","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/da.22026","volume":"29","author":"TD Zbozinek","year":"2012","unstructured":"Zbozinek TD, Rose RD, Wolitzky-Taylor KB, Sherbourne C, Sullivan G, Stein MB, Roy-Byrne PP, Craske MG. Diagnostic overlap of generalized anxiety disorder and major depressive disorder in a primary care sample. Depress Anxiety. 2012;29:1065\u201371.","journal-title":"Depress Anxiety"},{"key":"8836_CR70","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1002\/mco2.148","volume":"3","author":"JJ Zhang","year":"2022","unstructured":"Zhang JJ, Song CG, Dai JM, Li L, Yang XM, Chen ZN. Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu-opioid receptor. MedComm. 2022;3:e148.","journal-title":"MedComm"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08836-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08836-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08836-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T12:02:39Z","timestamp":1744891359000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08836-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8836"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08836-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflicts of interest with the research or writing of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}